Dr. Harikrishna KR Nair initiates a NATROX® O₂ Clinical Trial in Malaysia
Dr. Harikrishna KR Nair, head consultant of the Wound Care Unit, Department of Internal Medicine, at the Kuala Lumpur Hospital in Malaysia has initiated a 30-patient clinical trial.
The goal of the clinical trial is to evaluate the effectiveness of NATROX® Oxygen Wound Therapy on non-healing diabetic foot ulcers. The key end points of the study are the number of participants that achieve complete wound closure during the 12-week study and the percentage reduction in wound size after 12 weeks.
The study is already underway with 2 patients enrolled.
Dr. Harikrishna KR Nair commented that “after seeing promising results achieved with NATROX® O₂ in my clinical practice, it seemed sensible to formally evaluate the potential impact that NATROX® O₂ could have on patients affected by diabetic foot ulcers.”
It is estimated that 422 million (8.5%) of the world’s adult population has diabetes. Malaysia has an even greater prevalence; in 2014, it was estimated that 2.6 million Malaysians had diabetes, which equates to over 15% of the total population and we know that people with diabetes have a one-in-four risk of developing a diabetic foot ulcer (DFU) in their lifetime.
The study will be held at the HKL Hospital in Kuala Lumpur in Malaysia and the enrolment phase is expected to run for 4 months.